Trial · NCT01134055
Results by group2,234
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 2,234
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Change From Baseline in Best-corrected Visual Acuity (BCVA) as Measured by the Number of Letters Read on the Early Treatment of Diabetic Retinopathy Study (ETDRS) Grading Charts at a Starting Distance of 4 Meters at Week 52 | Placebo Control Arm QID | 0.22 | Standard Error 1.006 | Letters | |
Change From Baseline in Best-corrected Visual Acuity (BCVA) as Measured by the Number of Letters Read on the Early Treatment of Diabetic Retinopathy Study (ETDRS) Grading Charts at a Starting Distance of 4 Meters at Week 52 | Pazopanib Eye Drops 5 mg/mL TID | 1.15 | Standard Error 1.004 | Letters | |
Change From Baseline in Best-corrected Visual Acuity (BCVA) as Measured by the Number of Letters Read on the Early Treatment of Diabetic Retinopathy Study (ETDRS) Grading Charts at a Starting Distance of 4 Meters at Week 52 | Pazopanib Eye Drops 5 mg/mL QID | 1.81 | Standard Error 0.975 | Letters | |
Change From Baseline in Best-corrected Visual Acuity (BCVA) as Measured by the Number of Letters Read on the Early Treatment of Diabetic Retinopathy Study (ETDRS) Grading Charts at a Starting Distance of 4 Meters at Week 52 | Pazopanib Eye Drops 10 mg/mL BID | 0.76 | Standard Error 0.995 | Letters | |
Change From Baseline in Best-corrected Visual Acuity (BCVA) as Measured by the Number of Letters Read on the Early Treatment of Diabetic Retinopathy Study (ETDRS) Grading Charts at a Starting Distance of 4 Meters at Week 52 | Pazopanib Eye Drops 10 mg/mL TID | 0.28 | Standard Error 0.992 | Letters | |
Change From Baseline in Best-corrected Visual Acuity (BCVA) as Measured by the Number of Letters Read on the Early Treatment of Diabetic Retinopathy Study (ETDRS) Grading Charts at a Starting Distance of 4 Meters at Week 52 | Pazopanib Eye Drops 10 mg/mL QID | 0.62 | Standard Error 1.007 | Letters | |
Change From Baseline in Best-corrected Visual Acuity (BCVA) as Measured by the Number of Letters Read on the Early Treatment of Diabetic Retinopathy Study (ETDRS) Grading Charts at a Starting Distance of 4 Meters at Week 52 | Ranibizumab Injections Active Open-label Control Arm | 1.42 | Standard Error 1.020 | Letters | |
| Percentage of Ranibizumab Re-injections Received Over 28 and 52 Weeks | Placebo Control Arm QID | Injection Rate at 28 Weeks | 65.04 | Standard Error 3.418 | Percentage of re-injections |
| Percentage of Ranibizumab Re-injections Received Over 28 and 52 Weeks | Pazopanib Eye Drops 5 mg/mL TID | Injection Rate at 28 Weeks | 55.03 | Standard Error 3.441 | Percentage of re-injections |
| Percentage of Ranibizumab Re-injections Received Over 28 and 52 Weeks | Pazopanib Eye Drops 5 mg/mL QID | Injection Rate at 28 Weeks | 67.92 | Standard Error 3.395 | Percentage of re-injections |
| Percentage of Ranibizumab Re-injections Received Over 28 and 52 Weeks | Pazopanib Eye Drops 10 mg/mL BID | Injection Rate at 28 Weeks | 66.11 | Standard Error 3.418 | Percentage of re-injections |
| Percentage of Ranibizumab Re-injections Received Over 28 and 52 Weeks | Pazopanib Eye Drops 10 mg/mL TID | Injection Rate at 28 Weeks | 61.61 | Standard Error 3.418 | Percentage of re-injections |
| Percentage of Ranibizumab Re-injections Received Over 28 and 52 Weeks | Pazopanib Eye Drops 10 mg/mL QID | Injection Rate at 28 Weeks | 59.42 | Standard Error 3.441 | Percentage of re-injections |
| Percentage of Ranibizumab Re-injections Received Over 28 and 52 Weeks | Placebo Control Arm QID | Overall Injection Rate at 52 weeks | 64.24 | Standard Error 3.263 | Percentage of re-injections |
| Percentage of Ranibizumab Re-injections Received Over 28 and 52 Weeks | Pazopanib Eye Drops 5 mg/mL TID | Overall Injection Rate at 52 weeks | 55.09 | Standard Error 3.286 | Percentage of re-injections |
| Percentage of Ranibizumab Re-injections Received Over 28 and 52 Weeks | Pazopanib Eye Drops 5 mg/mL QID | Overall Injection Rate at 52 weeks | 65.87 | Standard Error 3.241 | Percentage of re-injections |
| Percentage of Ranibizumab Re-injections Received Over 28 and 52 Weeks | Pazopanib Eye Drops 10 mg/mL BID | Overall Injection Rate at 52 weeks | 62.50 | Standard Error 3.263 | Percentage of re-injections |
| Percentage of Ranibizumab Re-injections Received Over 28 and 52 Weeks | Pazopanib Eye Drops 10 mg/mL TID | Overall Injection Rate at 52 weeks | 64.42 | Standard Error 3.263 | Percentage of re-injections |
| Percentage of Ranibizumab Re-injections Received Over 28 and 52 Weeks | Pazopanib Eye Drops 10 mg/mL QID | Overall Injection Rate at 52 weeks | 58.19 | Standard Error 3.286 | Percentage of re-injections |
| Number of Participants With BCVA Over Time | Placebo Control Arm QID | Week 4, Study Eye / within 5 letters | 49 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01134055/results